Skip to main content
. 2016 Mar 29;10:415–423. doi: 10.2147/PPA.S100175

Figure 2.

Figure 2

Scatter plot of estimated joint density of incremental cost (2015 USD) and incremental effectiveness (QALYs) of raloxifene versus conventional treatment obtained from probabilistic sensitivity analyses.

Notes: Mean incremental cost is USD 221 and mean incremental effectiveness is 0.006 QALYs for raloxifene versus conventional treatment. Dotted line denotes the WTP threshold, the plots to the right of the WTP threshold are cost-effective. Given a WTP threshold of USD 20,000 per QALY gained, treatment with raloxifene has a 45% probability of being cost-effective.

Abbreviations: QALY, quality-adjusted life year; WTP, willingness-to-pay; USD, United States Dollars.